Key result
Dutogliptin in combination with filgrastim is being evaluated in a phase 2 trial to determine if it improves left ventricular ejection fraction at 90 days compared to placebo in patients with STEMI.
Why the study?
Previous regenerative therapies requiring invasive procedures after STEMI yielded inconclusive results, prompting the evaluation of combining stem cell mobilization using G-CSF with DPP4 inhibition via dutogliptin.
Does dutogliptin in combination with filgrastim improve left ventricular ejection fraction in patients with STEMI and reduced EF following PCI?
RCT (n=140)
Double-blind
Interactive web response system (IRT)
Yes
Does dutogliptin in combination with filgrastim improve left ventricular ejection fraction in patients with STEMI and reduced EF following PCI?
Answers are grounded in this paper and cite their sources.
This protocol describes a phase 2 trial testing whether the combination of dutogliptin and filgrastim improves left ventricular ejection fraction in patients recovering from STEMI.
BACKGROUND: Regenerative therapies offer new approaches to improve cardiac function after acute ST-elevation myocardial infarction (STEMI). Previous trials using bone marrow cells, selected stem cell populations, or cardiac stem cell progenitors require invasive procedures and had so far inconclusive results. A less invasive approach utilizes granulocyte-colony stimulating factor (G-CSF) to mobilize stem cells to circulating blood and induce neovascularization and differentiation into endothelial cells and cardiomyocytes. Stromal cell-derived factor 1 alpha (SDF-1α) is an important chemokine for initiating stem cell migration and homing to ischemic myocardium. SDF-1α concentrations can be increased by inhibition of CD26/DPP4. Dutogliptin, a novel DPP4 inhibitor, combined with stem cell mobilization using G-CSF significantly improved survival and reduced infarct size in a murine model. METHODS: We test the safety and tolerability and efficacy of dutogliptin in combination with filgrastim (G-CSF) in patients with STEMI (EF < 45%) following percutaneous coronary intervention (PCI). Preliminary efficacy will be analyzed using cardiac magnetic resonance imaging (cMRI) to detect > 3.8% improvement in left ventricular ejection fraction (LV-EF) compared to placebo. One hundred forty subjects will be randomized to filgrastim plus dutogliptin or matching placebos. DISCUSSION: The REC-DUT-002 trial is the first to evaluate dutogliptin in combination with G-CSF in patients with STEMI. Results will lay the foundation for an appropriately powered cardiovascular outcome trial to test the efficacy of this combined pharmacological strategy. TRIAL REGISTRATION: EudraCT no.: 2018-000916-75 . Registered on 7 June 2018. IND number: 123717.
No takes yet. Share an insight, caveat, or question.
Lewinski et al. (2020) conducted an RCT in ST-elevation myocardial infarction (STEMI) (n=140). Dutogliptin and filgrastim vs. Matching placebo was evaluated on Change in left ventricular ejection fraction (LV-EF) from baseline to day 90 assessed by cardiac magnetic resonance imaging (cMRI). Dutogliptin in combination with filgrastim is being evaluated in a phase 2 trial to determine if it improves left ventricular ejection fraction at 90 days compared to placebo in patients with STEMI.
Synapse has enriched 10 related papers. Consider them for comparative context: